Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Oncology stories

Oct 14, 2026

FDA expands Anktiva approval for bladder cancer treatment

The FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer, expanding the drug's approved indications.

Oct 14, 2026·2 sources
00

Vir Biotechnology and Gilead partner on $1.88B cancer therapy deal

Vir Biotechnology signed a collaboration agreement worth up to $1.88 billion with Gilead Sciences to discover and develop T cell engager treatments for solid tumors, with Gilead paying $65 million upfront and $45 million in near-term milestones.

Oct 14, 2026·2 sources
00
Sep 11, 2026

FDA extends review of Exelixis colorectal cancer drug by three months

The FDA has extended its review period for Exelixis' experimental colorectal cancer drug combination by three months, delaying a regulatory decision.

Sep 11, 2026·2 sources
00
Aug 28, 2026

Moderna raises $2.6B following major cancer vaccine trial success

Moderna completed an upsized note offering to support its cancer work shortly after achieving a significant win in a crucial clinical study of its mRNA cancer vaccine developed with Merck.

Aug 28, 2026·2 sources
00
May 31, 2026

Johnson & Johnson's Prostate Cancer Drug Reduces Risk of Cancer Spread and Death in Late-Stage Study

J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.

May 31, 2026·2 sources
00

Novartis Experimental Radiopharma Drug Shows Anti-Tumor Activity in Early Prostate Cancer Study

Novartis reported early data showing its experimental actinium-based radiopharma drug demonstrated anti-tumor activity against prostate cancer, including in patients previously treated with its older therapies.

May 31, 2026·1 source
00
Apr 22, 2026

Immunotherapy Shows Clinical Benefit in Advanced Colorectal Cancer as First-Line Treatment

Clinical trial results demonstrate that immunotherapy as first-line treatment provides clinical benefit for patients with advanced colorectal cancer, offering an alternative to chemotherapy for a disease increasingly affecting younger patients.

Apr 22, 2026·2 sources
00
Apr 21, 2026

CAR-T Therapy Shows Promise in Preventing Multiple Myeloma in High-Risk Patients

Early trial results presented at AACR show CAR-T cell therapy may prevent smoldering multiple myeloma from progressing to active disease in high-risk patients, representing a potential preventive approach to cancer treatment.

Apr 21, 2026·2 sources
00
Apr 17, 2026

Datopotamab Deruxtecan Nearly Doubles Survival in Triple-Negative Breast Cancer Trial

Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.

Apr 17, 2026·1 source
00
Apr 14, 2026

Revolution Medicines Pancreatic Cancer Drug Doubles One-Year Survival in Clinical Trial

A new drug developed at Northwestern University showed patients with pancreatic cancer living twice as long as those on chemotherapy in a Phase III trial, with former Sen. Ben Sasse among participants.

Apr 14, 2026·3 sources
00
Apr 13, 2026

Pembrolizumab Significantly Improves Survival in Platinum-Resistant Ovarian Cancer

A study published in The Lancet shows that pembrolizumab (Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian cancer, a difficult-to-treat patient population.

Apr 13, 2026·1 source
00

Teen and Young Adult Cancer Survivors Face Double the Risk of Developing Later Cancers

Research published in the Canadian Medical Association Journal found that survivors of cancer during their teen and young adult years face twice the risk of developing most types of subsequent cancers compared to the general population.

Apr 13, 2026·1 source
00
Apr 7, 2026

Gilead Acquires German Cancer Biotech Tubulis for Over $3 Billion

Gilead Sciences is acquiring German biotech company Tubulis for more than $3 billion in a deal that will expand its oncology pipeline with antibody-drug conjugate technology.

Apr 7, 2026·1 source
00

St. Jude and Partners Develop Data Platform Unifying Blood Cancer Genomics and Clinical Data

Scientists at St. Jude Children's Research Hospital, the American Society for Hematology, and Munich Leukemia Laboratory created a data-sharing platform that unites genomics, gene expression, and clinical data for blood cancers.

Apr 7, 2026·1 source
00

Top claims

  • ▪Anktiva, a bladder cancer treatment, is administered at a 400 µg dose directly into the bladder via catheter alongside Bacillus Calmette-Guérin once weekly for 6 weeks as initial induction therapy
  • ▪The most common adverse reactions reported with Anktiva and Bacillus Calmette-Guérin treatment include dysuria, hematuria, urinary frequency, urinary tract infections, musculoskeletal pain, chills, pyrexia, and elevated creatinine
  • ▪FDA Oncology Center of Excellence director R. Angelo de Claro stated that review of shared cancer features allowed the agency to expand treatment options for papillary tumors

Topics

ImmunotherapyFDA drug approvalCancer treatment breakthroughsDrug developmentDrug Approval and Clinical TrialsDrug Policy, Pricing & ApprovalVaccine development and innovationClinical trialsCancer treatmentVaccine developmentPharmaVaccines and Immunization PolicyCancer & OncologyCancer Treatment & TherapiesCancer TypesCancer immunotherapyPublic healthcareCAR T-cell therapyCancer preventionClinical evaluationClinical Trial Design & EvaluationPreventive longevity physiciansLongevity & biohackingHealthLongevity biotech foundersAI data analysisHematology & Blood Cancers

Related entities

Bladder cancerUnited StatesMerckHormone therapyProstate cancerColorectal cancerPreventive medicineBreast cancerBevacizumabGermany